Abstract:
:Patients diagnosed with advanced gastrointestinal stromal tumor (GIST) are currently treated with oral tyrosine kinase inhibitors (TKIs). Imatinib mesylate is the standard first-line treatment, and sunitinib malate is administered second-line for patients who are intolerant or progress on imatinib. Imatinib has recently been approved for adjuvant treatment of GIST patients who have a significant risk for relapse. In both the metastatic and adjuvant settings, patients may be on these TKIs for many years. Low plasma imatinib levels have been reported to be associated with a short median time to progression of advanced GIST, stressing the importance of maintaining optimal drug levels. We summarize management of the most frequent and clinically significant adverse effects of imatinib and sunitinib in the treatment of GIST in the context of current guidelines, published literature, and the experience of three large GIST referral centers. The adverse events reviewed include nausea and vomiting, diarrhea, skin rash, musculoskeletal complaints, fatigue, hemorrhage, edema, hand-foot skin reaction, skin and hair discoloration, mucositis, hypertension, cardiac toxicity, hypothyroidism, liver transaminase changes, and hematological toxicity of imatinib and sunitinib. Potential drug-drug interactions with each respective agent are also discussed. With prudent use of supportive care measures, many side effects can be managed without dose reduction or interruption of treatment. On the other hand, individualized tailoring of the dose is often required to manage severe toxicity, such as painful hand-foot skin reactions, fatigue, hepatotoxicity, or cardiac toxicity. Management of many TKI-related adverse effects require further evaluation in prospective clinical trials.
journal_name
Cancer Treat Revjournal_title
Cancer treatment reviewsauthors
Joensuu H,Trent JC,Reichardt Pdoi
10.1016/j.ctrv.2010.04.008subject
Has Abstractpub_date
2011-02-01 00:00:00pages
75-88issue
1eissn
0305-7372issn
1532-1967pii
S0305-7372(10)00086-1journal_volume
37pub_type
杂志文章,评审abstract::Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with relatively poor prognosis, earlier disease recurrence and higher number of visceral metastases. Despite an increasing understanding of the molecular heterogeneity of TNBC, clinical trials of targeted agents have thus far...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2016.09.004
更新日期:2016-11-01 00:00:00
abstract::Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways,...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2018.12.002
更新日期:2019-02-01 00:00:00
abstract::Resistance to tyrosine-kinase inhibitors remains an open issue in the treatment of patients with gastrointestinal stromal tumors. The complex biology of disease in the multi-resistant setting has led a progressively growing urgency and interest in development combined or integrated therapies. This mini-review outlines...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2009.10.004
更新日期:2010-02-01 00:00:00
abstract::Infertility is a common and distressing late-effect of cancer treatment. Whist sperm banking for post-pubertal males and embryo freezing for women (who are in a stable relationship at the time of treatment) are highly successful fertility preservation strategies, for females without a partner (including young and pre-...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2007.02.001
更新日期:2007-11-01 00:00:00
abstract::We have established that drug resistance can be expressed following in vitro exposure of tumour cells not only to antitumor drugs but also to fractionated X-irradiation. These data therefore suggest a biological basis for the clinical problem of drug resistance that can occur in patients with previously irradiated tum...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/0305-7372(90)90012-5
更新日期:1990-12-01 00:00:00
abstract:BACKGROUND:The immune system plays an important role in cancer pathogenesis. A low lymphocyte-to-monocyte ratio (LMR), as a simple biomarker of host immune system, has been suggested to be related to poor prognosis in various cancers. We performed a systematic review and meta-analysis to quantify the prognostic value o...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,meta分析,评审
doi:10.1016/j.ctrv.2015.10.003
更新日期:2015-12-01 00:00:00
abstract::Arsenic is a semi-metal or metalloid with two biologically important oxidation states, As(III) and As(V). As(III), in particular, reacts with closely spaced protein thiols, forming stable cyclic dithioarsinite complexes in which both sulfur atoms are bound to arsenic. It is this reaction that is mostly responsible for...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2007.05.001
更新日期:2007-10-01 00:00:00
abstract::Metastatic colorectal cancer (CRC) is most frequently seen in the liver. Resection of metastases remains the treatment of choice; however, the majority of patients are ineligible for surgery due to unfavorable location, size, or number of metastases; insufficient liver reserve; or extrahepatic disease. The activity of...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.01.004
更新日期:2008-06-01 00:00:00
abstract:BACKGROUND:Surgery is the only curative treatment for primary cutaneous melanoma, therefore it is important to determine excision margins that minimise risk of local recurrence, distant recurrence and death. METHODS:MEDLINE, EMBASE and Cochrane CENTRAL were searched from 2009 to 2015. Inclusion criteria were: populati...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,meta分析,评审
doi:10.1016/j.ctrv.2015.10.013
更新日期:2016-01-01 00:00:00
abstract::Immunotherapy represents a major breakthrough in cancer therapy in recent years. Immune-checkpoint blockade using PD-1 and PD-L1 antibodies appears to be one of the most promising immunotherapy approaches. Immunotherapy differs from conventional cancer treatment because of its ability to produce durable responses in s...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2015.09.004
更新日期:2015-12-01 00:00:00
abstract::Twenty patients with malignant lymphomas refractory to prior combination chemotherapy were treated with ifosfamide (40 mg/kg/day i.v. days 1-5) and etoposide (120 mg/m2/day i.v., days 1, 3, 5). Altogether, 56 courses of treatment were given with prophylaxis of urinary side effects by mesna (8 mg/kg i.v. 0, 4, 8 hours ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/s0305-7372(83)80019-x
更新日期:1983-09-01 00:00:00
abstract::This review summarizes emerging information regarding the Hedgehog (Hh) signaling pathway during neoplastic transformation in the gastrointestinal tract. Although there is a role for the well-established canonical pathway in which Hedgehog ligands interact with their receptor Patched, there is sufficient evidence that...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2013.08.003
更新日期:2014-02-01 00:00:00
abstract::Patients with solid tumours are at risk of impaired bone health from metastases and cancer therapy-induced bone loss (CTIBL). We review medical management of bone health in patients with solid tumours over the past 30 years, from first-generation bisphosphonates to the receptor activator of nuclear factor κB ligand (R...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2019.05.003
更新日期:2019-06-01 00:00:00
abstract::Cancer cells exhibit deregulation in multiple cellular signaling pathways. Therefore, treatments using specific agents that target only one pathway usually fail in cancer therapy. The combination treatments using chemotherapeutic agents with distinct molecular mechanisms are considered more promising for higher effica...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2009.07.001
更新日期:2009-11-01 00:00:00
abstract::There has been much progress in the understanding of the relationship between the immune system and colorectal cancer. This has led to the use of immunomodulatory therapy in the adjuvant and palliative treatment of the condition. Although attempts at the use of non-specific immunomodulation with agents such as levamis...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1053/ctrv.1999.0160
更新日期:2000-06-01 00:00:00
abstract::RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (cod...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2015.05.008
更新日期:2015-09-01 00:00:00
abstract::The HER2 oncogene encodes a transmembrane protein partially homologous to epidermal growth factor receptor. This oncogene has been studied mainly in breast cancer where it has prognostic, predictive and therapeutic target value. The expression of HER2 in epithelial ovarian cancer has been less studied. HER2 expression...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2006.01.001
更新日期:2006-05-01 00:00:00
abstract::Prostate cancer is one of the leading causes of cancer related death in men, and remains incurable in the metastatic setting. Despite the initial response to androgen deprivation, the disease gradually progresses to a hormone-refractory state due to cumulative genetic alterations in tumour cells or the microenvironmen...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2009.06.001
更新日期:2010-04-01 00:00:00
abstract::Glioblastoma is the most malignant and frequent primary brain tumour in adults. Current treatment remains insufficient as these tumours display a diffuse infiltrative growth pattern and tend to recur despite extensive debulking surgery followed by radio- and chemotherapy. The alkylating agents carmustine (1,3-bis-(2-c...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2008.03.125
更新日期:2008-10-01 00:00:00
abstract::Prostate cancer is the most common malignancy in elderly men and is often associated with bone metastases. Although bone metastases are osteosclerotic, histological and biochemical studies clearly indicate an increase of both bone formation and bone resorption, providing the rational for using bisphosphonate as a pall...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1053/ctrv.2000.0213
更新日期:2001-06-01 00:00:00
abstract::The technique of sentinel node biopsy (SNB) presents a great opportunity to reduce the morbidity of surgical treatment of breast cancer. Using either dye, isotope or a combination, after completing a learning process a sensitivity of 80-99% may be achieved. Most surgeons would aim for a sensitivity of 95% but this wil...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1053/ctrv.2002.0251
更新日期:2002-02-01 00:00:00
abstract::The availability of sensitive methods has allowed the detailed study of circulating tumor cells only recently. Evolving evidence support the prognostic and predictive role of these cells in patients affected by several solid tumors, including colorectal cancer. Ongoing studies are aimed at confirming that the molecula...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2012.12.007
更新日期:2013-11-01 00:00:00
abstract::Microtubule stabilization by chemotherapy is a powerful weapon in the war against cancer. Disruption of the mitotic spindle activates a number of signaling pathways, with consequences that may protect the cell or lead to its death via apoptosis. Taxol, the first microtubule stabilizing drug to be identified, has been ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2006.01.004
更新日期:2006-05-01 00:00:00
abstract::Checkpoint blockades turn on a new paradigm shift in immunotherapy for cancer. Remarkable clinical efficacy, durable response and low toxicity of programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockades have been observed in various malignancies. However, a lot of cancer patients failed to resp...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2015.11.001
更新日期:2015-12-01 00:00:00
abstract::Targeted therapies have unique toxicity profiles. Common adverse events include rash, diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity. Some of these toxicities are caused by on-target, mechanism-associated effects, which can be stratified as to whether or not the targets are rel...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2014.05.003
更新日期:2014-08-01 00:00:00
abstract::The clinical trials of bisantrene are still at an early stage. However, the many Phase II trials currently ongoing in the Southwest Oncology Group are too premature to draw any firm conclusions. However, there was general agreement during the discussion period that bisantrene does have definite clinical activity in ce...
journal_title:Cancer treatment reviews
pub_type: 杂志文章
doi:10.1016/0305-7372(84)90024-0
更新日期:1984-12-01 00:00:00
abstract:BACKGROUND:Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard regimen for first- or second-line chemotherapy (CT). This review aims to give an overview of the hot topics concerning treatment, prognostic factors and new strategies in ad...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2012.09.007
更新日期:2013-02-01 00:00:00
abstract::Adolescent patients with cancer reside in a "no-man's land" between the world of pediatric oncology and that of "adult" medical oncology. As compared to younger and older patients, adolescents and young adults are under-represented on clinical trials. This relative lack of participation in clinical protocols has been ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2006.11.005
更新日期:2007-11-01 00:00:00
abstract::Non-small cell lung cancer (NSCLC) accounts for >80% of lung cancer cases and currently has an overall five-year survival rate of only 15%. Patients presenting with advanced stage NSCLC die within 18-months of diagnosis. Metastatic spread accounts for >70% of these deaths. Thus elucidation of the mechanistic basis of ...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2013.10.001
更新日期:2014-05-01 00:00:00
abstract::Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may b...
journal_title:Cancer treatment reviews
pub_type: 杂志文章,评审
doi:10.1016/j.ctrv.2012.06.003
更新日期:2013-04-01 00:00:00